Elevation of serum C-reactive protein predicts failure of the initial antimicrobial treatment for febrile neutropenia with lung cancer

被引:2
作者
Matsumoto, Takemasa [1 ]
Fujita, Masaki [1 ]
Hirota, Takako [1 ]
Takeda, Satoshi [1 ]
Hirano, Ryousuke [1 ]
Uchino, Junji [1 ]
Harada, Taishi [1 ]
Watanabe, Kentaro [1 ]
机构
[1] Fukuoka Univ Hosp, Dept Resp Med, Jonan Ku, Fukuoka 8140180, Japan
关键词
Risk factor; Febrile neutropenia; Lung cancer; CRP; COMMUNITY-ACQUIRED PNEUMONIA; INFECTIOUS-DISEASES-SOCIETY; GUIDELINES; AGENTS; SEVERITY;
D O I
10.1007/s10156-012-0474-8
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Febrile neutropenia frequently develops after chemotherapy, and the prompt administration of antimicrobial agents is required for treatment. In the present study, we searched for predictive factors for the failure of the initial antimicrobial agents used for febrile neutropenia (FN) in patients with lung cancer. Sixty FN patients treated in our ward from June 2005 to May 2011 were retrospectively analyzed. The definition of FN and the response to antimicrobial agents were determined by the Japanese guidelines. We divided the FN patients into two groups by their response to the initial antimicrobial agents. Next, the characteristics of the two groups were compared. The Multinational Association of Supportive Care in Cancer (MASCC) score did not differ between the two groups. The non-responder group demonstrated significant elevation of serum C-reactive protein (CRP) level. A multivariate analysis demonstrated that a CRP level higher than 10 mg/dl is an independent risk factor for the failure of initial antimicrobial agents for FN with lung cancer (OR 11.0, 95 % CI 1.635-74.5). When the CRP score was added to the MASCC score, the scoring system could more precisely predict the failure of initial antimicrobial agents in patients with lung cancer who developed febrile neutropenia.
引用
收藏
页码:202 / 207
页数:6
相关论文
共 22 条
  • [2] [Anonymous], INT J HEMATOL
  • [3] [Anonymous], 2009, RESPIROLOGY
  • [4] Plasma C-Reactive Protein Levels Are Associated With Improved Outcome in ARDS
    Bajwa, Ednan K.
    Khan, Uzma A.
    Januzzi, James L.
    Gong, Michelle N.
    Thompson, Taylor
    Christiani, David C.
    [J]. CHEST, 2009, 136 (02) : 471 - 480
  • [5] C-reactive protein is an independent predictor of severity in community-acquired pneumonia
    Chalmers, James D.
    Singanayagam, Aran
    Hill, Adam T.
    [J]. AMERICAN JOURNAL OF MEDICINE, 2008, 121 (03) : 219 - 225
  • [6] Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer
    Fleischhack, G
    Hartmann, C
    Simon, A
    Wulff, B
    Havers, W
    Marklein, G
    Hasan, C
    Bode, U
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 47 (06) : 841 - 853
  • [7] Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
    Freifeld, Alison G.
    Bow, Eric J.
    Sepkowitz, Kent A.
    Boeckh, Michael J.
    Ito, James I.
    Mullen, Craig A.
    Raad, Issam I.
    Rolston, Kenneth V.
    Young, Jo-Anne H.
    Wingard, John R.
    [J]. CLINICAL INFECTIOUS DISEASES, 2011, 52 (04) : E56 - E93
  • [8] Identifying risk factors for refractory febrile neutropenia in patients with lung cancer
    Fujita, Masaki
    Tokunaga, Shoji
    Ikegame, Satoshi
    Harada, Eiji
    Matsumoto, Takemasa
    Uchino, Junji
    Watanabe, Kentaro
    Nakanishi, Yoichi
    [J]. JOURNAL OF INFECTION AND CHEMOTHERAPY, 2012, 18 (01) : 53 - 58
  • [9] Clinical efficacy and safety of cefepime in febrile neutropenic patients with lung cancer
    Fujita, Masaki
    Ouchi, Hiroshi
    Inoue, Yuichi
    Inoshima, Ichiro
    Ohshima, Tsukasa
    Yoshimura, Chikara
    Wataya, Hiroshi
    Kawasaki, Masayuki
    Tokunaga, Shoji
    Nakanishi, Yoichi
    [J]. JOURNAL OF INFECTION AND CHEMOTHERAPY, 2010, 16 (02) : 113 - 117
  • [10] Immunity, Inflammation, and Cancer
    Grivennikov, Sergei I.
    Greten, Florian R.
    Karin, Michael
    [J]. CELL, 2010, 140 (06) : 883 - 899